Toyota|$17.82 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.17 (¥4,312)-1.21%▼ (in JPY terms)
SoftBank|$19.06 (¥3,025)-14.48%▼ (in JPY terms)
MUFG|$19.06 (¥3,024)-5.41%▼ (in JPY terms)
Keyence|$88.38 (¥14,025)-4.53%▼ (in JPY terms)
Nintendo|$55.65 (¥8,832)-5.09%▼ (in JPY terms)
NTT|$1.06 (¥168)-0.71%▼ (in JPY terms)
Takeda|$43.94 (¥6,973)+0.33%▲ (in JPY terms)
Tokyo Electron|$52.36 (¥8,309)-7.06%▼ (in JPY terms)
Recruit|$106.09 (¥16,835)-5.50%▼ (in JPY terms)
ITOCHU|$14.17 (¥2,248)-1.88%▼ (in JPY terms)
Honda|$10.94 (¥1,737)-2.99%▼ (in JPY terms)
Shin-Etsu|$33.00 (¥5,237)-5.28%▼ (in JPY terms)
Tokio Marine|$3.64 (¥578)+2.03%▲ (in JPY terms)
Fast Retailing|$518.11 (¥82,220)-1.38%▼ (in JPY terms)
Toyota|$17.82 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.17 (¥4,312)-1.21%▼ (in JPY terms)
SoftBank|$19.06 (¥3,025)-14.48%▼ (in JPY terms)
MUFG|$19.06 (¥3,024)-5.41%▼ (in JPY terms)
Keyence|$88.38 (¥14,025)-4.53%▼ (in JPY terms)
Nintendo|$55.65 (¥8,832)-5.09%▼ (in JPY terms)
NTT|$1.06 (¥168)-0.71%▼ (in JPY terms)
Takeda|$43.94 (¥6,973)+0.33%▲ (in JPY terms)
Tokyo Electron|$52.36 (¥8,309)-7.06%▼ (in JPY terms)
Recruit|$106.09 (¥16,835)-5.50%▼ (in JPY terms)
ITOCHU|$14.17 (¥2,248)-1.88%▼ (in JPY terms)
Honda|$10.94 (¥1,737)-2.99%▼ (in JPY terms)
Shin-Etsu|$33.00 (¥5,237)-5.28%▼ (in JPY terms)
Tokio Marine|$3.64 (¥578)+2.03%▲ (in JPY terms)
Fast Retailing|$518.11 (¥82,220)-1.38%▼ (in JPY terms)

Otsuka Holdings Co.,Ltd. (4578)

TSE 4578 · Pharmaceuticals

Otsuka Holdings Co.,Ltd.

大塚ホールディングス株式会社
$78.08 (¥12,390)
-95.0 (-0.76%)in JPY terms
Delayed quote · Yahoo Finance
🏢 Industry: Pharmaceuticals
🌐 ISIN: JP3188220002
📊 TSE: 4578
Company Overview

Otsuka Holdings is a diversified Japanese healthcare group with major businesses in pharmaceuticals, nutraceuticals, and consumer products. The company is best known internationally for its psychiatric and neurological medicines, as well as for the Pocari Sweat sports drink brand, which has achieved significant market penetration across Asia.

For international investors, Otsuka Holdings presents a distinctive combination of branded pharmaceuticals and consumer health products, providing a degree of earnings diversification uncommon among pure-play pharmaceutical companies. The group's psychiatric medicine portfolio, including treatments for schizophrenia and bipolar disorder, generates revenues across major global markets, while its consumer nutraceutical and beverage businesses contribute stable cash flows primarily across the Asia-Pacific region.

Recent Press Releases
2026-11-142026-11-13 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory has launched a new enteral nutrition formula, "Innofeed® Enteral Solution."”2026-11-062026-11-05 Otsuka Holdings Co.,Ltd. “Taiho Pharmaceutical and Taiho Oncology presented the results of the AZTOUND trial of an oral azacitidine-cedazuridine combination drug for myelodysplastic syndrome or chronic myelomonocytic leukemia at the 68th Annual Meeting of the American Society of Hematology.”2026-11-052026-11-04 Otsuka Holdings Co.,Ltd. “Paradise Ultrasound Renal Denervation System: Shows blood pressure reduction effect at 12 months and sustained effect over 4 years (link to Recor English page).”2026-10-282026-10-27 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory has launched a new product, "Hynex® Egel 1.5," a concentrated liquid food with a calorie concentration of 1.5 kcal/mL, designed to accommodate dietary restrictions on intake and fluid intake.”2026-10-272026-10-26 Otsuka Holdings Co.,Ltd. “Otsuka BioVentures, a US-based corporate venture capital firm, has officially launched, accelerating collaborations with promising startups through strategic equity investments.”2026-10-242026-10-23 Otsuka Holdings Co.,Ltd. “The final results of the Phase 3 trial of the IgA nephropathy treatment drug "VOYXACT® (sibeprenelimab)" were presented at the American Society of Nephrology (ASN) meeting – demonstrating stabilization of renal function and reduction of the risk of disease progression and renal failure, offering new hope to patients with IgA nephropathy.”2026-10-232026-10-22 Otsuka Holdings Co.,Ltd. “Taiho Pharmaceutical installs new solar power generation equipment at its drug discovery center in Tsukuba – promoting carbon neutrality initiatives.”2026-10-202026-10-19 Otsuka Holdings Co.,Ltd. “Zipalertinib demonstrates clinically meaningful intratracranial antitumor activity in patients with NSCLC with EGFR exon 20 insertion or uncommon EGFR mutations and active CNS metastases (link to Taiho Oncology English page).”2026-10-172026-10-16 Otsuka Holdings Co.,Ltd. “Paradise Ultrasonic Renal Denervation System wins TIME magazine's "Best Inventions of 2026" award (link to Recor English page).”2026-10-172026-10-16 Otsuka Holdings Co.,Ltd. “Notice of price revision for some products – effective for deliveries from January 1st, 2027 (Friday).”
Key Data
52W High
$80.63 (¥12,795)
52W Low
$52.40 (¥8,316)
TSE Code
4578
ISIN
JP3188220002